Introduction 18
Thousands of risk loci have been identified by Genome Wide Association Studies 19 (GWAS) affecting nearly all studied common complex diseases in humans 20 (Welter et al., 2014 , and http://www.ebi.ac.uk/gwas/). However, for the vast 21 majority of risk loci the causative variants and genes remain unknown. This 22 knowledge is essential to fully capitalize on the investments in GWAS, including 23 for the development of improved diagnostic and therapeutic applications. 24
A number of issues complicate the identification of the causative variants by 25 association analysis. The first is that the utilized case-control cohorts are usually 26 genotyped for only a subset of the variants segregating in the population. Ideally, 27 fine-mapping would require sequencing of all cases and controls in the 28 chromosome regions of interest, if not the entire genome. This will remain 29 difficult to achieve, at least in the short term. At present, the best alternative is 30 genotype imputation using for instance the data from the 1,000 Genomes Project 31 as reference set. However, the reliability of the imputed genotypes is not perfect, 32 particularly for low frequency and rare variants. Thus the information content 33 varies between variants. In other words, the effective number of genotypes may 34 vary between variants, precluding fair comparison of the strength of their 35 association. 36 A second issue is the difficulty, when using the most commonly applied single-37 marker analyses (i.e. testing for disease association one marker at a time), to 38 distinguish the association patterns of the causative variants from that of 39 "passenger" variants that are merely in linkage disequilibrium (LD) with 40 causative variants. In the case of allelic homogeneity (one causative variant 41 only), one "asymptotically" expects the causative variant to show the strongest 42 single-marker association (highest -log(p) value) of all variants. But in the real 43 world the causative variant may be overshadowed by passenger variants that by 44 chance (or as a result of unaccounted confounding effects), and given the limited 45 size of the case-control cohorts, appear more strongly associated with the 46 disease. The situation becomes even trickier in the case of allelic heterogeneity 47 (i.e. the segregation of multiple causative risk variants that may or may not be in 48 LD), a scenario that is likely to be very common. In this case, the lead SNP in 49 single-marker analysis may be a "ghost" variant that is in LD with two or more 50 causative variants, hence being "asymptotically" more strongly associated with 51 the disease than either of them. Also, in the case of allelic heterogeneity, 52 causative variants are by definition bound to exist amongst the "non lead" 53 variants in single-marker analysis. 54
Improving the mapping resolution by analysis of association requires the 55 development of statistical models that allow inclusion of confounding factors, 56 estimation of the effects of individual variants conditional on the other ones (i.e. 57 multi-marker analysis to distinguish causative from passenger variants), and 58 identification of the best amongst the large number of possible models (i.e. what 59 combination of variants, assumed to be causative, explains the data best 
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BayesFM algorithm 71
Assumptions. We assume that GWAS studies have identified one or more risk 72 loci for a disease of interest in an available case-control cohort. We further 73 assume that -within the identified risk loci -the genotypes of array-interrogated 74
SNPs have been augmented in cases and controls with genotypes of as many 75 variants as possible either by imputation or by sequencing. We herein propose 76
an approach that will model disease outcome as a function of the genotypes at 77 one or more variants in a given risk locus with the aim to fine map that locus, i.e. 78 to identify causative variants within that locus. Fine-mapping is conducted one 79 risk locus at the time. Risk loci defined by GWAS typically span ∼250 Kb, contain 80 ∼5 genes (range: 0 to >50) and encompass thousands of common and low 81 frequency variants. 82
Model. The proposed model is based on the standard assumption of an 83 underlying, normally distributed liability y with threshold t, such that individuals 84 for which y > t are affected and individuals for which y ≤ t are healthy. We model 85 the liability of individual i (yi) as 86 
The population mean, , and effects of the PCs capturing population stratification 103 are assumed to follow uniform distributions ( ∝ 1; ! ∝ 1). Following 104 Fang et al. (2012) , the prior distribution of the effect of variant j from m, ! , is 105 assumed to follow a double-exponential distribution: 106
which is factorized in three sub-priors: (i) normally distributed
Posterior distributions for Gibbs sampling. Effects ! are sampled from normal 110 distributions with mean 111
and variance 112
in which n is the total number of analyzed individuals (cases + controls). 1 ! ! 113 are sampled from inverse Gaussian distributions 114
The hyper-parameters ! ! are sampled from gamma distributions 115
PC effects, ! , are sampled from normal distributions with mean 116
and variance 117
The population mean, , is sampled from a normal distribution with mean 118
and variance 1 . 119
For affected individuals ( ! = 1 ), the liabilities, ! , are sampled from the 120 truncated normal distributions (such that ! > ) with density 121
For unaffected individuals ( ! = 0), the liabilities, ! , are sampled from the 122 truncated normal distributions (such that ! ≤ ) with density 123
corresponds to the cumulative 124 density from −∞ to t. 125
Variant sampling using the Metropolis-Hastings algorithm. We first 126 hierarchically cluster variants that are in high LD using (1-r 2 ) as distance 127 measure and the "single linkage" approach implemented with the R "hclust" 128 package. By doing so variants in distinct clusters will never have r 2 > C, yet 129 variants within clusters may have r 2 < C. We tested C values of 0.9 and 0. clusters. When a substitute variant is selected, the probability to "accept" it is 139
where 140 variants, we update , the ! 's and ! 's by one round of Gibbs sampling. The 150 complete process was repeated 500,000 (simulated data) or 1 million times (realdata). The first 100,000 (simulated data) or 500,000 cycles (real data) were 152 used as burn-in and ignored when compiling the summary statistics. 153
Summarizing the results. We computed posterior probabilities (PP) for 154 clusters as well as individual variants from the proportion of MCMC cycles in 155 which they were included in the model. Within clusters, we defined "credible 156 sets" of markers by ranking them on PP and considering the minimal set of 157 markers that would jointly account for 95% of the PP of the cluster. 158
Clusters with posterior probability ≥ 0.50 were retained for further validation by 159 fitting their corresponding lead SNPs jointly in a logistic regression model. 160
Clusters exceeding the set significance threshold were considered to be positive. 161
We used thresholds of 10 -4 , 10 -6 and 10 -8 that might be considered as locus-162 specific, multi-locus (∼100 loci; cfr. Huang et al., 2016) and genome-wide 163
thresholds. 164 165
Forward Selection 166
The performance of BayesFM was compared with that of a standard forward 167 selection approach implemented by logistic regression in R. Significance 168 thresholds were the same as defined above (10 -4 , 10 -6 and 10 -8 ). We built 169 credible sets associated with selected "lead" (l) variants by computing the PP for 170 all n variants in high LD (r 2 > C, as defined above) with l. The PP probability of 171 variant j of n was computed as: 172 which may cause ! ! to deviate from 2%. Indeed, 202
Thus, we rescaled the effects ! to ! * = ! 2% ! ! . Substituting ! * for ! in the 203 previous equation indeed gives ! ! = 2%. 204
To generate a simulated case-control cohort we sampled 1 million individuals 205 from the Immunochip dataset with replacement and without discrimination of 206 real case-control status. For each of these, we generated a liability, ! , as (i) the 207 sum of the genotype effects at the 1, 3 or 5 causative variants:
(ii) a residual effect, ! , drawn from a normal distribution with mean 0 and 209 variance of 1. Thus the variance explained by the locus as a fraction of the total 210 liability variance is in fact 0.02 1 + 0.02 ≈ 0.02. Assuming an incidence of the 211 disease of 1/400, we kept the 2,500 individuals with highest liability as case 212 cohort. We randomly sampled 2,500 individuals from the remaining 1,000,0002,500 = 997,500 individuals to serve as controls. We generated 100 such 214 (Table 1 and Supplemental Table 1 ). Mapping resolution 233 (defined as the size of the credible sets) was comparable between BayesFM and 234 FS and only very mildly affected by significance threshold and variance explained. 235
As expected, it decreased with LD threshold used to define clusters/credible sets 236 (average number of variants per cluster/credible set of ∼25 (r 2 =0.9) versus ∼30 237 (r 2 =0.5)). Otherwise, LD threshold (r 2= 0.5 or 0.9) had only very modest effects 238 on TPR . 239
For given thresholds and variance explained, the TPR tended to be slightly better 240
for BayesFM than for FS, especially at the higher significance thresholds, but the 241 differences were modest (Table 1 and Supplemental Table 1 higher for FS than for BayesFM (Table 1 and Supplemental Table 1 is shown in Figure 2B and Table 2 . 278
Real data. We then examined the results obtained with BayesFM on the NOD2 279 locus (chr16: 50,692,364-50,847,022), a well-established risk locus for Crohn's 280 disease. We analyzed the dataset of the IIBDGC described in Huang et al. (2016) 281 and comprising 18,967 Crohn's disease cases and 34,257 matched controls. 282 Table 3 summarizes the results that were obtained using either r 2 > 0.9 or r 2 > 283 0.5 as LD threshold to define clusters of variants (see M&M). For both analyses, 284
we report the clusters with PP > 0.50. Thirteen such signals were obtained with 285 r 2 > 0.9, and fourteen with r 2 > 0.5. The average number of variants per signal 286 was 1.15 with r 2 > 0.9 and 3.14 with r 2 > 0.5. Single variant resolution was 287 obtained for 11/13 signals with r 2 > 0.9 and 8/14 signals with r 2 > 0.5, 288
highlighting the remarkable resolving power that can be achieved for at least 289 some loci with BayesFM. The log(1/p) value obtained by fitting the lead variant 290 (with highest PP) of each signal in a multivariate logistic regression, exceeded 6 291 for 10/13 signals with r 2 > 0.9 and 10/14 signals with r 2 > 0.9. The lowest 292 log(1/p) value was 3.33 for the signal that was detected using r 2 > 0.5 only. 
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